A Phase 1/2 clinical trial indicated a 12-month overall survival rate of 52.7% for IDH1 wild-type gliomas, thereby reinforcing the potential of this therapeutic strategy for treating refractory tumor types (154). This evidence concerns the gene IDH1 and central nervous system cancer.